Last updated on September 2018

A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors


Brief description of study

The main purpose of this study is to evaluate the safety and tolerability of anti-programmed cell death ligand 1 (PD-L1) checkpoint antibody LY3300054 in participants with advanced refractory solid tumors.

Clinical Study Identifier: NCT02791334

Contact Investigators or Research Sites near you

Start Over

YUNG-JUE BANG

Seoul National University Hospital
Seoul, Korea, Republic of
8.37miles
  Connect »

Hyun Cheol Chung

Severance Hospital Yonsei University Health System
Seoul, Korea, Republic of
8.37miles
  Connect »